InnovAtlasMalaria No More
Research institution

Portland State University and VA Portland Health Care System — T111 Antimalarial Program

Develop

Researchers at Portland State University and the VA Portland Health Care System are developing T111 and its prodrugs as antimalarial medicines active against the blood, liver, dormant liver, and mosquito stages of the malaria parasite.

2
Endemic countries
1
U.S. states
3
Products and programs
About

What they do

Researchers at Portland State University and the VA Portland Health Care System are developing T111 and its prodrugs as antimalarial medicines active against the blood, liver, dormant liver, and mosquito stages of the malaria parasite.1 T111 is active against drug-resistant parasites, including artemisinin-resistant clinical isolates, and works through a mechanism distinct from current antimalarials.1 The program's R&D is jointly based in Portland, Oregon, with in vivo blood-stage studies conducted at the VA.1 The work is in the development stage, with T111 and its prodrugs in preclinical development.1

In the United States
Products and programs

In the field and in development

T111, lead multi-stage acridone antimalarial candidate3,1
T111 prodrugs1
Transmission-blocking acridone sugar-bait approach1
Where they work

Partnerships in 2 endemic countries

Product testing
Rwanda
Africa
  • University of Rwanda and University Teaching Hospital of Butare, Huye · evaluation of T111 against artemisinin-resistant P. falciparum clinical isolates1
Uganda
Africa
  • Infectious Diseases Research Collaboration, Kampala · ex vivo testing of T111 against P. falciparum clinical isolates1
U.S. partners

Who they work with in the United States

Sources

Where this comes from

  1. 1Confirmed by the organization
  2. 2pdx.edu
  3. 3pdx.edu
  4. 4pdx.edu